PlainBillCongress, translated.Legislation. Context. Public interest.Congressional Research Service
No official summary is available in the imported record yet.
People & committees
Rep. Mace, Nancy [R-SC-1] · R–SC
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Referred to the Subcommittee on Health.
Referred to the House Committee on Veterans' Affairs.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We also preserved the text version used in the PlainBill explanation below.
No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.
Source last updated: Sep 24, 2026. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.10212 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.10212 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.10212 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.10212 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.
PlainBill explanation
Based on the full Introduced in House · 2026-09-01 text. This explanation has not received human editorial review. This overview describes the proposal’s major provisions; it does not establish what its real-world effects would be.
This bill would require the Department of Veterans Affairs (VA) to define peptide-based therapies and study their safety and possible benefits for veterans receiving care at VA medical facilities. If the Secretary determines in the study report that these treatments should be provided, VA would have to run a pilot program for veterans who choose to participate. The proposal would test the treatments; it does not establish that they work.
set forth a definition of peptide-based therapy for purposes of this Act
the Secretary of Veterans Affairs shall carry out a study on the safety, efficacy, and potential therapeutic benefits of peptide-based therapies for veterans receiving care at medical facilities of the Department of Veterans Affairs.
If the Secretary determines, in the report required by subsection (a)(4), that peptide-based therapies should be provided to such veterans, then the Secretary shall carry out a pilot program
Participation in the pilot program shall be limited to veterans who elect to participate
The proposal's short title is the PEPTIDES for Veterans Act.
This Act may be cited as the Providing Evidence-based Peptide Therapies to Improve Delivery and Expanded Services for Veterans Act or the PEPTIDES for Veterans Act.
The VA Secretary would have to review federal regulations and guidance concerning peptides, focusing on how the term is defined and any subsequent research developments. The Secretary would establish a definition of peptide for this bill's purposes.
The Secretary of Veterans Affairs shall conduct a review of the regulations and guidance relating to peptides and, in particular, the scope of peptide as a defined term in Federal regulations and guidance, and shall establish an appropriate definition of peptide for purposes of this Act.
A primary focus of the review shall be to consider addressing developments in research relating to peptides, if any, since the regulations, guidance, and defined terms were established.
Within 180 days after enactment, the Secretary would have to report to Congress on existing rules, definitions, and any research developments. The report would provide definitions of peptide and peptide-based therapy, any guidance the Secretary considers appropriate regarding what constitutes such a therapy, and an explanation of the peptide definition and any differences from other federal definitions.
Not later than 180 days after the date of the enactment of this Act, the Secretary shall submit to Congress a report on the results of the review.
The report shall— (1) summarize the regulations, guidance, and defined terms; (2) describe the research developments, if any, since the regulations, guidance, and defined terms were established; (3) set forth the definition of peptide established by the Secretary for purposes of this Act; (4) set forth a definition of peptide-based therapy for purposes of this Act and any guidance the Secretary determines to be appropriate regarding what constitutes such a therapy; and (5) explain the rationale for the definition established by the Secretary and the differences, if any, between such definition and other definitions of peptide in Federal regulations and guidance.
The safety and effectiveness study would begin when the definitions report is submitted to Congress. It would have to finish within 18 months of that submission.
Beginning on the date on which the report required by section 2 is submitted to Congress, the Secretary of Veterans Affairs shall carry out a study on the safety, efficacy, and potential therapeutic benefits of peptide-based therapies for veterans receiving care at medical facilities of the Department of Veterans Affairs.
The study shall be completed not later than the date that is 18 months after the date on which the report required by section 2 is submitted to Congress.
The study would review medical research, establish clinical protocols, identify possible uses for recovery, rehabilitation, chronic pain, mental health, physical wellness, and other service-connected conditions affecting veterans, and consider safety for clinical and rehabilitation purposes.
In carrying out the study, the Secretary shall— (A) review medical research; (B) establish clinical protocols; (C) identify potential applications relating to recovery, rehabilitation, chronic pain, mental health, physical wellness, and other service-connected conditions affecting veterans; and (D) consider the extent to which peptides are safe to use for clinical and rehabilitation purposes.
Upon completing the study, the Secretary would report findings and recommendations to Congress and determine whether peptide-based therapies should be available to veterans receiving care at VA medical facilities. A determination in that report that the therapies should be provided would require a pilot program that provides the therapies and assesses their results.
Upon completing the study, the Secretary shall submit to Congress a report on the results of the study. The report shall include findings, recommendations, and a determination as to whether peptide-based therapies should be made available to veterans receiving care at medical facilities of the Department of Veterans Affairs.
If the Secretary determines, in the report required by subsection (a)(4), that peptide-based therapies should be provided to such veterans, then the Secretary shall carry out a pilot program under which peptide-based therapies are made available to such veterans and the results of those therapies are assessed.
Pilot participation would be voluntary. The Secretary would also have to impose any geographic, clinical, or other limits the Secretary considers appropriate.
Participation in the pilot program shall be limited to veterans who elect to participate, and the Secretary shall impose such other geographic, clinical, or other limitations on the pilot program as the Secretary considers appropriate.
Any pilot would have to finish within five years after it is established. Upon completion, the Secretary would report to Congress on treatment effectiveness, including a determination of what conditions or ailments are improved by peptides, guidance on wider implementation across VA medical facilities, and challenges encountered.
The pilot program shall be completed not later than the date that is 5 years after the date on which it is established.
Upon completing the pilot program, the Secretary shall submit to Congress a report on the results of the pilot program. The report shall include— (A) a detailed description of the effectiveness of peptide treatments for clinical and rehabilitation purposes, including a determination as to what conditions or ailments are improved by use of peptides; (B) guidance on large-scale implementation of peptides throughout the medical facilities of the Department; and (C) any challenges encountered in carrying out the pilot program.
The supplied September 24, 2026 source snapshot records House introduction and referral to the House Committee on Veterans' Affairs on September 1, 2026, followed by referral to the Subcommittee on Health on September 8, 2026.
Source snapshot updated 2026-09-24T08:05:27Z. 2026-09-08: Referred to the Subcommittee on Health. 2026-09-01: Referred to the House Committee on Veterans' Affairs. 2026-09-01: Introduced in House
A closer look
Reviewed version: Introduced in House · 2026-09-01. These findings describe provisions and who may benefit; they are not judgments of waste, corruption, or motive.
This review covers the supplied bill text. “None identified” does not rule out provisions in later versions or accompanying reports and disclosures.
Provisions outside the bill’s main subject, or policy changes attached to appropriations.
None identified in the reviewed text
No unrelated provision or policy change attached to appropriations was identified in the complete supplied introduced text. This conclusion is limited to that version and does not establish absence in other versions or accompanying materials.
Spending directed to particular recipients or places outside ordinary competitive or formula-based allocation.
None identified in the reviewed text
No congressionally directed spending for particular recipients or places was identified in the complete supplied introduced text. This conclusion is limited to that version and does not establish absence in other versions or accompanying materials, or resolve formal earmark status beyond the supplied text.
Narrow exceptions, exemptions, or preferential treatment that warrant a closer look.
None identified in the reviewed text
No materially narrow carve-out, special exemption, or preferential treatment was identified in the complete supplied introduced text. Coverage of the program's intended beneficiaries does not alone qualify. This conclusion is limited to that version and does not establish absence in other versions or accompanying materials.
Full text preserved for this analysis. Legislative record snapshot: Sep 24, 2026. How PlainBill uses AI